ClinicalTrials.gg
Active, not recruitingNCT05169567postMONARCHUpdated Oct 6, 2026Results posted

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

A Phase 3 interventional study of Abemaciclib and Fulvestrant in Breast Neoplasm and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Active, not recruiting at 138 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
8th of 55
368 · median 120
Started
2022
with 2 others
Phase 3
11 of 55
2 open now
Primary completion
2024-02
later than 7 of 33 live
Registered
35th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 3 that started in 2022, is one of 11 in phase 3, reaches primary completion later than 7 of the 33 other live ones, and was the 35th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

03

Conditions studied

  • Breast Neoplasm
  • Neoplasm Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of HR+, - locally advanced or breast cancer
  • Have radiologic evidence of disease progression or recurrence either

    • On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
    • On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as therapy for early stage breast cancer
  • Must be deemed appropriate for treatment with ET
  • If female, have a status by natural or surgical means or by ovarian function suppression
  • Have Response Evaluable Criteria in Solid Tumors () evaluable disease ( and/or nonmeasurable disease)
  • Have a performance status of 0 or 1 on the scale (Oken et al. 1982)
  • Have adequate renal, hematologic, and hepatic organ function
  • Must be able to swallow capsules/tablets

Exclusion criteria

Exclusion Criteria:

  • Have visceral crisis, lymphangitic spread, or
  • Have symptomatic or untreated central nervous system
  • Have received any systemic therapy between disease recurrence/progression and study screening
  • Have received more than 1 for advanced or metastatic disease.
  • Have received prior chemotherapy for metastatic breast cancer (MBC)
  • Have received prior treatment with fulvestrant, any estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
368 participants (actual)

Study arms

  • Experimental
    Arm A: Abemaciclib plus Fulvestrant

    Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.

    Drug: Abemaciclib · Drug: Fulvestrant

  • Active comparator
    Arm B: Placebo plus Fulvestrant

    Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.

    Drug: Fulvestrant · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)

Secondary outcomes

  1. Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)

    PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)

  2. Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)

    ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

    Time frame: Randomization until measured progressive disease (Up to 22 Months)

07

Results

Posted Feb 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus Fulvestrant
Started182186
Received at least one dose of study drug181185
Completed4037
Not completed142149
Withdrew: On study treatment116128
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject2521

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsArm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus Fulvestrant
Progression-Free Survival (PFS)6 (5.6 to 8.1)5.3 (3.7 to 5.6)
Statistical analysis
  • Arm A: Abemaciclib Plus Fulvestrant vs Arm B: Placebo Plus Fulvestrant · Log Rank · p = 0.02 · Hazard ratio (hr): 0.73 · 95% CI 0.57 to 0.95
SecondaryProgression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)

PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
Reported as:
Median · Months
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
MonthsArm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus Fulvestrant
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)12.9 (9.5 to NA)5.6 (3.9 to 7.7)
SecondaryObjective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)

ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

Time frame:
Randomization until measured progressive disease (Up to 22 Months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Percentage of participantsArm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus Fulvestrant
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)2410

Adverse events

Collected over Baseline up to 22 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Abemaciclib Plus Fulvestrant40/181 (22.1%)44/181 (24.3%)173/181 (95.6%)
Arm B: Placebo Plus Fulvestrant37/185 (20%)20/185 (10.8%)131/185 (70.8%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventArm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus Fulvestrant
PneumoniaInfections and infestations8/1814/185
VomitingGastrointestinal disorders3/1810/185
Acute kidney injuryRenal and urinary disorders3/1810/185
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1810/185
AnaemiaBlood and lymphatic system disorders2/1811/185
Febrile neutropeniaBlood and lymphatic system disorders2/1810/185
HypothyroidismEndocrine disorders2/1810/185
Abdominal painGastrointestinal disorders2/1810/185
DiarrhoeaGastrointestinal disorders2/1811/185
NauseaGastrointestinal disorders2/1810/185
Most frequent other events
Showing 10 of 35
Most frequent other events
EventArm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus Fulvestrant
DiarrhoeaGastrointestinal disorders135/18131/185
NeutropeniaBlood and lymphatic system disorders73/1816/185
AnaemiaBlood and lymphatic system disorders63/18127/185
NauseaGastrointestinal disorders59/18134/185
FatigueGeneral disorders59/18143/185
Abdominal painGastrointestinal disorders41/18130/185
VomitingGastrointestinal disorders35/18111/185
ThrombocytopeniaBlood and lymphatic system disorders33/18111/185
Decreased appetiteMetabolism and nutrition disorders33/18112/185
LeukopeniaBlood and lymphatic system disorders32/1816/185

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Arm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus FulvestrantTotal
Mean58.00 ± 12.1559.60 ± 12.1658.80 ± 12.17
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus FulvestrantTotal
Female180185365
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus FulvestrantTotal
Hispanic or Latino282755
Not Hispanic or Latino135143278
Unknown or Not Reported191635
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus FulvestrantTotal
American Indian or Alaska Native325
Asian212647
Native Hawaiian or Other Pacific Islander000
Black or African American639
White140143283
More than one race000
Unknown or Not Reported121224
Region of Enrollment
Region of Enrollment(Participants)Arm A: Abemaciclib Plus FulvestrantArm B: Placebo Plus FulvestrantTotal
Argentina192039
Belgium7512
Czechia112
Denmark123
France111021
Greece8412
Hungary7916
Israel121123
Italy161127
Mexico549
Poland213
South Korea101020
Spain273158
Taiwan111425
Turkey172542
United States282856
08

Study locations

138 sites

Showing the first 100 of 138 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643. PubMed 40141282 ↗
  • Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18. PubMed 39693591 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Feb 2024, 22 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 22 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2021
First posted
Dec 27, 2021
StartActual
Mar 11, 2022
Primary completionActual
Feb 8, 2024
CompletionEst.
Dec 2027
Results first posted
Feb 27, 2025
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05169567
Responsible party
Sponsor
First posted
Dec 27, 2021
Start date
Mar 11, 2022
Primary completion
Feb 8, 2024
Completion
Dec 2027 (estimated)
Results posted
Feb 27, 2025
Last update
Oct 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion